ANDA 206211, held by Mission Pharmacal. Potassium Iodide.
As of Nov 16, 2026, ANDA 206211 (Potassium Iodide), held by Mission Pharmacal, was first approved by FDA on Mar 24, 2016, with 0 approved supplements and 0 published complete response letters.
Use Helps prevent radioactive iodine from getting into the thyroid gland during a nuclear radiation emergency. Use along with other emergency measures recommended by public officials.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 24, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Potassium Iodide65MG/ML · solution;oral | Potassium Iodide | OTC |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters